New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
10:55 EDTACAD, ACAD, ATTU, ATTU, CODE, CODE, AERI, AERI, EGAN, EGAN, IMAX, IMAX, SPNS, SPNS, JAKK, JAKK, CNAT, CNAT, BIRT, BIRT, BDSI, BDSI, PERI, PERIRoth Capital to hold a conference
26th Annual Growth Stock Conference is being held in Dana Point, California on March 9-12 with webcasted company presentations to begin on March 10 at 11 am; not all company presentations may be webcasted. Webcast Link
News For ACAD;BDSI;BIRT;CNAT;JAKK;SPNS;IMAX;EGAN;AERI;CODE;ATTU;PERI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 23, 2015
06:41 EDTCODECypress Semiconductor upgraded to Neutral from Underweight at JPMorgan
Subscribe for More Information
January 22, 2015
07:03 EDTCODESpansion sees Q1 revenue $270M-$310M, consensus $300.91M
Subscribe for More Information
07:03 EDTCODESpansion reports Q4 non-GAAP EPS 30c, consensus 30c
Subscribe for More Information
January 16, 2015
08:01 EDTCODECypress Semiconductor, Spansion receive early termination of HSR waiting period
Cypress Semiconductor (CY) and Spansion (CODE) announced tody that the U.S. Department of Justice and FTC have granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for their merger proposal. The companies have also received notification from Germany's Federal Cartel Office that the acquisition has been cleared to proceed. On December 1, 2014, Cypress and Spansion entered into a definitive agreement to merge in an all-stock, tax-free transaction valued at approximately $4B. The post-merger company will generate more than $2 billion in revenue annually and create a leading global provider of microcontrollers and specialized memories needed in today's embedded systems. Under the terms of the agreement, Spansion shareholders will receive 2.457 Cypress shares for each Spansion share they own. The shareholders of each company will own approximately 50 percent of the post-merger company.
January 15, 2015
08:56 EDTCODECypress Semiconductor shares defended on weakness, says Sterne Agee
Subscribe for More Information
07:31 EDTIMAXIMAX a Top Idea for 2015 at MKM Partners
MKM Partners named IMAX a Top Idea for 2015 and expects it to be a breakout year for the company due to a strong film slate, expanding China presence, and cost containment that will drive revenue growth and margin expansion. Shares are Buy rate with an increased price target of $36 from $34.
January 13, 2015
14:44 EDTACADACADIA says Nuplazid NDA submission planned for 1Q15
Subscribe for More Information
07:09 EDTATTUAttunity and a Cloud Services Company enter into technology license agreement
Subscribe for More Information
January 12, 2015
14:47 EDTIMAXIMAX to voluntarily delist from Toronto Stock Exchange
Subscribe for More Information
14:18 EDTAERIAerie accelerated data read-out a positive, says Cantor
Subscribe for More Information
06:36 EDTPERIPerion Network names Miki Kolko CTO
Subscribe for More Information
06:31 EDTAERIAerie Pharma accelerates of timeline for reporting results from Rhopressa trial
Aerie Pharmaceuticals announced the acceleration of the expected timeline for reporting efficacy results from the company’s 400-patient Phase 3 registration trial of RhopressaTM, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure in patients with glaucoma or ocular hypertension. Rocket 1 and a second Phase 3 registration trial will measure efficacy over three months. The primary efficacy endpoint of the trials is to demonstrate non-inferiority of RhopressaTM compared to timolol for the lowering of IOP. Timolol is the most widely used comparator in registration trials for lowering of IOP. In addition, there is a 12 month safety component to Rocket 2 and the Company is conducting a safety-only study in Canada, named “Rocket 3.” Pending the continued advancement of the RhopressaTM Phase 3 program and regulatory approvals, Aerie intends to commercialize RhopressaTM in North American markets and possibly Europe with its own sales force and will seek commercialization partners in other key territories, including Japan and possibly Europe. Aerie fully owns its product candidates, has no licenses, and has patent protection for both use and composition of matter through 2030.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use